Newsletter June 2022

2022-06-29

VD kommenterar Sommaren är här, och vi ser fram emot en solig och avkopplande ledighet inom kort även om vi är aktiva om så behövs. Men först är det dags att summera första halvåret av 2022 för Aptahem. Vi...

Read More

Aptahem confirms that lead candidate Apta-1 shows very good tolerability in the GLP tox studies

2022-06-23

Aptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously communicated preliminary results regarding positive safety profile for Apta-1. The GLP...

Read More

BioStock article: Aptahem’s new CMO on her role and vision

2022-06-20

BioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in...

Read More

Aptahem appoints Ingela Hallberg as new CMO

2022-06-01

Aptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management...

Read More